Targeted Therapy in the Management of Modern Craniopharyngiomas.
Publication/Presentation Date
4-20-2022
Abstract
BACKGROUND: The proximity of craniopharyngiomas (CPs) to critical neurovascular structures can lead to a host of neurologic and endocrine complications that lead to difficulty with surgical management. In this review, we examine the molecular and genetic markers implicated in CP, their involvement in tumorigenic pathways, and their impact on CP prognosis and treatment.
METHODS: We undertook a focused review of relevant articles, clinical trials, and molecular summaries regarding CP.
RESULTS: Genetic and immunological markers show variable expression in different types of CP.
CONCLUSIONS: Genetic and immunological markers show variable expression in different subtypes of CP. Several current molecular treatments have shown some success in the management of this disease. Additional clinical trials and targeted therapies will be important to improve CP patient outcomes.
Volume
27
Issue
4
First Page
136
Last Page
136
ISSN
2768-6698
Published In/Presented At
Reyes, M., Taghvaei, M., Yu, S., Sathe, A., Collopy, S., Prashant, G. N., Evans, J. J., & Karsy, M. (2022). Targeted Therapy in the Management of Modern Craniopharyngiomas. Frontiers in bioscience (Landmark edition), 27(4), 136. https://doi.org/10.31083/j.fbl2704136
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
35468695
Department(s)
Administration and Leadership
Document Type
Article